Li, N., Zhang, S., Song, Y., Huang, J., Li, Q., Liang, X., . . . Dou, Y. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: A multicenter, single-arm phase II trial. BMJ Publishing Group.
Chicago Style (17th ed.) CitationLi, Ning, et al. HX008, an Anti-PD1 Antibody, Plus Irinotecan as Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Multicenter, Single-arm Phase II Trial. BMJ Publishing Group.
MLA (9th ed.) CitationLi, Ning, et al. HX008, an Anti-PD1 Antibody, Plus Irinotecan as Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Multicenter, Single-arm Phase II Trial. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.